Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2014 1
2016 1
2019 1
2020 1
2021 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hereditary spastic paraplegia 43"
Page 1
Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial.
Diniz de Lima F, Faber I, Servelhere KR, Bittar MFR, Martinez ARM, Piovesana LG, Martins MP, Martins CR Jr, Benaglia T, de Sá Carvalho B, Nucci A, França MC Jr. Diniz de Lima F, et al. Mov Disord. 2021 Jul;36(7):1654-1663. doi: 10.1002/mds.28523. Epub 2021 Feb 17. Mov Disord. 2021. PMID: 33595142 Clinical Trial.
BACKGROUND: Hereditary spastic paraplegia presents spasticity as the main clinical manifestation, reducing gait quality and producing incapacity. ...The objective of the current study was to evaluate the efficacy and safety of BoNT-A in patients with …
BACKGROUND: Hereditary spastic paraplegia presents spasticity as the main clinical manifestation, reducing gait …
Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia.
Margetis K, Korfias S, Boutos N, Gatzonis S, Themistocleous M, Siatouni A, Dalivigka Z, Flaskas T, Stranjalis G, Boviatsis E, Sakas D. Margetis K, et al. Clin Neurol Neurosurg. 2014 Aug;123:142-5. doi: 10.1016/j.clineuro.2014.05.024. Epub 2014 Jun 4. Clin Neurol Neurosurg. 2014. PMID: 24973568 Clinical Trial.
OBJECTIVE: We study the effectiveness and safety of intrathecal baclofen therapy for the treatment of spasticity and gait improvement in patients suffering from hereditary spastic paraplegia. METHODS: Sixteen patients diagnosed with hereditary spast …
OBJECTIVE: We study the effectiveness and safety of intrathecal baclofen therapy for the treatment of spasticity and gait improvement in pat …
Validation of the Italian version of a patient-reported outcome measure for Hereditary Spastic Paraplegia.
Diella E, D'Angelo MG, Stefan C, Girardi G, Morganti R, Martinuzzi A, Biffi E. Diella E, et al. PLoS One. 2024 Apr 1;19(4):e0301452. doi: 10.1371/journal.pone.0301452. eCollection 2024. PLoS One. 2024. PMID: 38557877 Free PMC article.
BACKGROUND AND AIM: Patient-reported outcome measures (PROMs) are recognized as valuable measures in the clinical setting. In 2018 we developed the Italian version of the "Hereditary Spastic Paraplegia-Self Notion and Perception Questionnaire" (HSP-SNA …
BACKGROUND AND AIM: Patient-reported outcome measures (PROMs) are recognized as valuable measures in the clinical setting. In 2018 we …
Improving gait adaptability in patients with hereditary spastic paraplegia (Move-HSP): study protocol for a randomized controlled trial.
van de Venis L, van de Warrenburg BPC, Weerdesteyn V, van Lith BJH, Geurts ACH, Nonnekes J. van de Venis L, et al. Trials. 2021 Jan 7;22(1):32. doi: 10.1186/s13063-020-04932-9. Trials. 2021. PMID: 33413555 Free PMC article.
BACKGROUND: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet environmental demands, a skill required for safe and independent ambulation. ...In addition, this study aims to identify key determinants of C-Mill …
BACKGROUND: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet environ …
The Effect of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Hereditary Spastic Paraplegia.
Antczak J, Pera J, Dąbroś M, Koźmiński W, Czyżycki M, Wężyk K, Dwojak M, Banach M, Slowik A. Antczak J, et al. Neural Plast. 2019 May 12;2019:7638675. doi: 10.1155/2019/7638675. eCollection 2019. Neural Plast. 2019. PMID: 31214256 Free PMC article. Clinical Trial.
BACKGROUND: Hereditary spastic paraplegia (HSP) is a heterogeneous group of inherited disorders affecting predominantly the motor cortex and pyramidal tract, which results in slowly progressing gait disorders, as well as spasticity and weakness of lower extre …
BACKGROUND: Hereditary spastic paraplegia (HSP) is a heterogeneous group of inherited disorders affecting predominantly …
Topiramate-Responsive Tremor in a Novel Pathogenic Variant of SPG15 Patient.
Ersen A, Gençpınar P, Arıcan P, Bozkaya Yılmaz S, Aliyeva N, Özdemir TR, Öztekin Ö, Olgaç Dündar N. Ersen A, et al. Clin Neuropharmacol. 2020 Jul/Aug;43(4):121-122. doi: 10.1097/WNF.0000000000000392. Clin Neuropharmacol. 2020. PMID: 32501858
Hereditary spastic paraplegia (HSP) is group of a rare neurodegenerative disorder with both genetically and clinically diverse neurologic features. ...Tremor in HSP patients is only mentioned with rare case reports, so treatment option is lack in clinical …
Hereditary spastic paraplegia (HSP) is group of a rare neurodegenerative disorder with both genetically and clinically …
A rare case of SPG11 mutation with multiple sclerosis.
Laurencin C, Rascle L, Cotton F, Grosset-Janin C, Bernard E, Depienne C, Vukusic S, Thobois S. Laurencin C, et al. Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):389-91. doi: 10.1016/j.neurol.2016.03.006. Epub 2016 May 11. Rev Neurol (Paris). 2016. PMID: 27180005
We describe a patient with SPG11 hereditary spastic paraplegia (HSP), who developed walking disorder in childhood. ...
We describe a patient with SPG11 hereditary spastic paraplegia (HSP), who developed walking disorder in childhood. ...
Intrathecal baclofen normalizes motor strategy for squatting in familial spastic paraplegia: a case study.
Dan B, Cheron G. Dan B, et al. Neurophysiol Clin. 2000 Feb;30(1):43-8. doi: 10.1016/S0987-7053(00)88866-8. Neurophysiol Clin. 2000. PMID: 10740795
We aimed to assess whether intrathecal baclofen could alter the motor strategy for squatting of a patient with pure familial spastic paraplegia. Before baclofen injection and two, four and six hours after it, the patient was evaluated as follows: self-report of walk …
We aimed to assess whether intrathecal baclofen could alter the motor strategy for squatting of a patient with pure familial spastic …